补肾化瘀法联合沙利度胺治疗多发性骨髓瘤的临床疗效研究

发布时间：2018-04-05 18:06

本文选题：补肾化瘀法　切入点：沙利度胺　出处：《世界中医药》2017年01期

【摘要】：目的:对补肾化瘀法联合沙利度胺治疗多发性骨髓瘤的临床疗效进行评价。方法:将120例多发性骨髓瘤患者分为2组进行对比治疗,其中对照组采用VAD方案,治疗组才对照组的基础上使用补肾化瘀法联合沙利度胺治疗。结果:经过治疗后,治疗组的患者总有效率达到75%,对照组的患者总有效率达到60%。2组有效率比较差异有统计学意义(P0.05);在M蛋白、骨髓浆细胞、成骨细胞和破骨细胞等各项指标上,2组与治疗前相比均有明显下降,而治疗组下降较对照组更为明显(P0.05),在肾功能、生活治疗和不良反应评估上,治疗组患者较对照组患者所受化疗的影响更小。结论:补肾化瘀法联合沙利度胺治疗多发性骨髓瘤的临床疗效更为显著,并且具有不良反应较少和治疗后患者的生活质量较高的优点,具有较大的临床应用价值,值得进行推广。
[Abstract]:Objective: to evaluate the clinical effect of tonifying kidney and removing blood stasis combined with thalidomide in the treatment of multiple myeloma.Methods: 120 patients with multiple myeloma were divided into two groups: the control group was treated with VAD regimen and the treatment group was treated with tonifying kidney and removing blood stasis combined with thalidomide.Results: after treatment, the total effective rate of the patients in the treatment group was 75 and that in the control group was 60.2. The difference was statistically significant in the M protein, bone marrow plasma cells,The indexes of osteoblast and osteoclast were significantly decreased in the two groups compared with before treatment, while the decrease in the treatment group was more obvious than that in the control group (P 0.05), in renal function, life therapy and adverse reaction evaluation.The effect of chemotherapy on the patients in the treatment group was less than that in the control group.Conclusion: the therapy of tonifying kidney and removing blood stasis combined with thalidomide is more effective in the treatment of multiple myeloma and has the advantages of less adverse reactions and higher quality of life after treatment.It is worth popularizing.
【作者单位】：河北省保定市第一中心医院中药房;
【基金】：河北省卫生厅资助基金(编号:hb28123)
【分类号】：R733.3

【参考文献】